Back to top
more

Amneal Pharmaceuticals (AMRX)

(Delayed Data from NSDQ)

$8.38 USD

8.38
1,835,514

+0.33 (4.10%)

Updated Aug 23, 2024 03:59 PM ET

After-Market: $8.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for AMRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for AMNEAL PHARMACEUTICALS, INC falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 99 35 257 347 153
Receivables 615 742 664 640 606
Notes Receivable 0 0 0 0 0
Inventories 581 531 489 491 381
Other Current Assets 83 104 110 73 70
Total Current Assets 1,378 1,412 1,520 1,552 1,210
Net Property & Equipment 448 470 514 478 478
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 1,489 1,695 1,760 1,827 1,802
Deposits & Other Assets 56 103 21 32 44
Total Assets 3,473 3,799 3,940 4,006 3,666
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 1 0
Accounts Payable 535 538 583 614 507
Current Portion Long-Term Debt 213 90 31 44 21
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 84 110 48 8 6
Total Current Liabilities 847 753 677 677 550
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 2,427 2,632 2,718 2,772 2,609
Non-Current Capital Leases 0 0 0 60 61
Other Non-Current Liabilities 42 97 49 87 40
Minority Interest (Liabilities) 41 25 17 12 0
Total Liabilities 3,453 3,615 3,573 3,661 3,319
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 3 3 3 3 3
Capital Surplus 539 692 658 628 607
Retained Earnings -490 -406 -276 -287 -378
Other Equity -32 -105 -18 0 115
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 20 184 367 345 347
Total Liabilities & Shareholder's Equity 3,473 3,799 3,940 4,006 3,666
Total Common Equity 20 184 367 345 347
Shares Outstanding 306.50 303.60 301.50 299.70 299.10
Book Value Per Share 0.07 0.61 1.22 1.15 1.16

Fiscal Year End for AMNEAL PHARMACEUTICALS, INC falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 50 52 99 96 115
Receivables 779 670 615 693 675
Notes Receivable 0 0 0 0 0
Inventories 576 571 581 576 551
Other Current Assets 82 87 83 91 82
Total Current Assets 1,485 1,380 1,378 1,456 1,422
Net Property & Equipment 425 440 448 452 459
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 1,418 1,458 1,489 1,581 1,615
Deposits & Other Assets 77 74 56 89 93
Total Assets 3,510 3,456 3,473 3,687 3,701
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 619 559 535 558 513
Current Portion Long-Term Debt 436 213 213 107 150
Current Portion Capital Leases 0 0 0 0 3
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 44 47 84 80 98
Total Current Liabilities 1,114 834 847 761 777
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 2,178 2,420 2,427 2,583 2,590
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 126 42 53 48
Minority Interest (Liabilities) 53 47 41 37 32
Total Liabilities 3,567 3,520 3,453 3,533 3,550
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 3 3 3 3 3
Capital Surplus 546 539 539 715 708
Retained Earnings -576 -582 -490 -392 -401
Other Equity -30 -24 -32 -173 -159
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -57 -64 20 154 151
Total Liabilities & Shareholder's Equity 3,510 3,456 3,473 3,687 3,701
Total Common Equity -57 -64 20 154 151
Shares Outstanding 309.50 308.60 306.50 306.40 306.10
Book Value Per Share -0.19 -0.21 0.07 0.50 0.49